Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
The 9th Project and Portfolio Management for Pharma & Biotech East or West – Learn from the best
In a time when pharma R&D costs are increasing and mergers & acquisitions are at an all-time high, the industry needs to consider its next steps.
Learn both practice and the art of research plus summarize the latest insights from both industry professionals and strategic decision makers. Portfolio management can be whatever senior management makes of it. It involves a broad mix containing everything from strategic management, decision making, risk evaluation and innovative thinking through different portfolio and product strategies to navigating between regulatory issues and market demands.
Do you want to learn:
· How disruptive projects are different?
· Why to launch them and how to manage them?
· How to achieve rewards?
· How to manage risk at the portfolio level?
· How to balance costs and new drug approvals?
· How to innovate in R&D?
Join The 9th Project and Portfolio Management for Pharma and Biotech – East, 9th - 10th March 2016, in Philadelphia. Are you busy during these dates or do you live closer to the west coast area?
Then join The 9th Project and Portfolio Management for Pharma and Biotech – West held 11th - 12th April 2016 in San Francisco.
Bringing together senior executives from pharma and biotech, these events seek to explore new advancements in portfolio management. Professionals from companies such as Eli Lilly and Company, Johnson & Johnson Innovation, Pfizer, AstraZeneca, Novartis and Allergan are on board.
How will you learn?
· CEO roundtable
· Interactive platform
· Point-of-View session hosted by industry leaders
· Real-world case studies
· Practical exercises
Over 10 hours of knowledge sharing and 8 hours of networking over coffee, lunch and cocktails make these events not to be missed.
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Driving the national agenda of Medical tourism through PX Excellence
Read the interview with Dr. Layla Al-Marzouqi, Director of Medical Tourism Council at Dubai Health Authority, and learn how to enrich patient experience and quality of healthcare.
No more trouble with dangerous good shipments
Global temperature controlled pharmaceutical shipments are constantly faced with new logistics challenges and regulations. This January 2017, IATA Dangerous Goods Regulations added further complexity to shipping cold chain products compliantly.
5 Changes in Signal Detection Management
The European Medicines Agency, regulatory authorities in the Member States and marketing authorisation holders are responsible for detecting and managing safety signals. A safety signal is generally defined as information about a new or known Adverse Event that may have been caused by a medicine, where it is therefore necessary to conduct further investigation. Evaluation of safety signals plays a major role within pharmacovigilance. Therefore, it is vital for regulatory authorities to know the latest updates detailing the risks and benefits of medicines. The EudraVigilance database is an important source of information on suspected adverse reactions and signals.